Thromboembolic events associated with immune checkpoint inhibitors in cancer patients: A Bayesian network meta-analysis
Open Access
- 22 December 2024
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 246, 109243
Abstract
No abstract availableKeywords
Funding Information
- Shaanxi Province Key Research and Development Projects (2023-YBSF-447)
- Natural Science Basic Research Program of Shaanxi Province (2021JM-272, 2020JQ-504)
This publication has 43 references indexed in Scilit:
- Blood Clots, or Thrombosis, in Patients With CancerJAMA Oncology, 2023
- Venous thromboembolism in cancer patients: ESMO Clinical Practice GuidelineAnnals of Oncology, 2023
- Immune-related adverse events in various organs caused by immune checkpoint inhibitorsAllergology International, 2022
- Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysisCancer Treatment Reviews, 2021
- Understanding and treating the inflammatory adverse events of cancer immunotherapyCell, 2021
- Adverse events induced by immune checkpoint inhibitorsCurrent Opinion in Immunology, 2021
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Thrombin—unique coagulation system protein with multifaceted impacts on cancer and metastasisCancer and Metastasis Reviews, 2016
- Fibrinolysis and the control of blood coagulationBlood Reviews, 2015
- Checking consistency in mixed treatment comparison meta‐analysisStatistics in Medicine, 2010